34 results about "Vasoactive agent" patented technology

A method of and a device for non-invasively measuring the neurological depressed state and the hemodynamic state of a human patient and involving steps and units of non-invasively measuring EEG, cardiac cycle period, electrical-mechanical interval, mean arterial pressure, and ejection interval and converting the EEG into a neurological index as well as converting the measured electrical-mechanical interval, mean arterial pressure and ejection interval into the cardiac parameters such as Preload, Afterload and Contractility, which are the common cardiac parameters used by an anesthesiologist. A general anesthetic is administered based upon the converted neurological index. A vasoactive agent is independently administered based upon the converted cardiac parameters as necessary in order to restore cardiovascular homeostasis in the patient. The converted neurological and hemodynamic state of a patient are displayed on a screen as an index value and a three-dimensional vector with each of its three coordinates respectively representing Preload, Afterload and Contractility. Therefore, a medical practitioner looks at the screen and quickly obtains the important and necessary information.

A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. for example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient. The formulation is sufficiently hygroscopic so as to create a condition of hypertonicity when absorbed by the skin. When the formulation is applied to the skin, the vasoactive agent can be delivered to the dermis so as to contact the vasculature of a patient.

The present invention describes novel nitrosated and/or nitrosylated α-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated α-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one α-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

Methods for treating female sexual dysfunction are provided. A pharmaceutical composition containing a vasoactive agent selected from vasoactive intestinal potypeptide (VIP) and VIP agonists is administered to the vagina and/or vulvar region of the individual undergoing treatment. The formulations are also useful for improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. Pharmaceutical formulations and kits are also provided.

The present invention describes novel nitrosated and/or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and/or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cardiovascular disorders, cerebrovascular disorders, hypertension, asthma, baldness, urinary incontinence, epilepsy, sleep disorders, gastrointestinal disorders, migraines, irritable bowel syndrome and sensitive skin.

A treatment for male erectile dysfunction comprising separately storing a lyophilized composition of vasoactive agents and a carrier gel, mixing said lyophilized composition of vasoactive agents and said carrier gel creating a homogeneous mixture and applying said homogeneous mixture to the meatus of the glans penis. A system for the treatment of male erectile dysfunction comprising a syringe coupling system for the storage, mixing and application of therapeutic compounds for the treatment of erectile dysfunction, said system further comprising a first syringe and a second syringe. The first and second syringes are filled with a lyophilized composition of vasoactive agents or a carrier gel. The system includes a locking device coupling said syringes to facilitate the transfer of said lyophilized composition of vasoactive agents and carrier gel between the syringes and a penile adapter for applying the therapeutic compounds for the treatment of erectile dysfunction to the meatus of the glans penis.

Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.

The present invention relates to topical drug compositions and methods for topical drug delivery which promote stability of a drug component and facilitate the penetration of the drug component into the skin of the host. The invention also relates to topical drug compositions containing a suitable vasoactive agent, such as a prostaglandin, and methods for effectively delivering said active ingredient to the host. These compositions and methods are useful for the treatment of sexual dysfunction, in both men and women. The invention also relates to methods for formulating or preparing the composition of the present invention. To minimize irritation, the composition is water based.

A female stimulation device comprising a resilient device body having a partially deformable tip portion, a flange and an intermediate side wall portion extending outwardly from the tip portion to the flange. In use, the tip portion is compressed to force air out of the device body and the flange is placed in contact with vaginal wall tissue so that the clitoris is encompassed by the device body. Release and restorative deformation of the tip portion causes a partial vacuum within the device body, which maintains the device in place and provides suction to the clitoris. The intermediate side wall portion is substantially non-deformable in response to deformation of the tip portion, as may be achieved with outwardly convex side walls, thereby preventing deleterious entrapment and compression of the clitoris. Pharmacologically active materials, such as vasoactive agents, substances, and medications, may be applied to the device for contact with the clitoris during use in order to further enhance female sexual function.

The invention belongs to the technical field of arterial blood pressure measurement. The invention provides a correcting method for pulse wave propagation time related to diastolic pressure. The correcting method is adopted for self-adaptively correcting the abnormal change in the pulse wave propagation time related to diastolic pressure resulted from blood transfusion and infusion, vasoactive agents and operation intervention under clinic conditions. The correcting method provided by the invention comprises the following steps: detecting ear pulse waves and toe pulse waves in a same cardiac cycle in real time; calculating the pulse wave propagation time related to diastolic pressure; extracting a correcting variable according to the morphological characteristics of the pulse waves; acquiring a correcting matrix; and correcting the abnormal change in the pulse wave propagation time. The propagation time after being corrected can be applied to the present mathematic model, the diastolic pressure in each cardiac cycle can be continuously measured under the clinic conditions, and the accuracy is high.

The invention relates to a ligustrazine stilbene derivative. The vascular activity of 63 new ligustrazine stilbene derivatives is screened, and a vascular ring separation perfusion method is used for researching the pharmacology mechanism for vessel dilatation, so that the vessel dilatation activity of C26b has notable endothelial dependence, and is mediated by an eNOS way. The vessel dilatation mediated by smooth muscle is mainly relevant to external calcium influx, calcium-activated potassium channels (KCa), and inward rectification type potassium channels (KIR) caused by restraining VDCC opening, and at the later stage, the ligustrazine stilbene derivative can be used for preparing drugs for vessel dilatation.

Transgene-inserted vectors are effectively used for in vivo gene therapy for peripheral vascular disease, heart disease and other conditions, by direct injection of the vector into arteries supplying the tissue to be targeted, preferably in combination with a vasoactive agent that is infused into the artery prior to or coincident with delivery of the vector.

The invention discloses a steroids non-depolarization muscle relaxant antagonistic pharmaceutical composition. The composition comprises 6-deoxy alpha-amino acid derivative cyclodextrin, metoclopramide, angiotensin II, anhydrous sodium acetate, sodium bisulfate, and citric acid. The 6-deoxy alpha-amino acid derivative cyclodextrin is a main component of the pharmaceutical composition; metoclopramide is an antiemetic, anhydrous sodium acetate and sodium bisulfite are added for assisting, and are co-effected on a dopamine receptor in a medulla oblongata chemoreceptor trigger zone, so that a threshold of the chemoreceptor trigger zone is increased; the angiotensin II is one of vaso-excitor active substances, and whole body arteriole contraction and arterial blood pressure rise can be realized; and the adverse symptoms such as decreased heart rate and drop of blood pressure of the steroids muscle relaxant antagonistic pharmaceutical composition can be effectively solved while in use, the pharmaceutical composition realizes combined action, and the steroids non-depolarization muscle relaxant antagonistic pharmaceutical composition capable of effectively reducing vomit and reducing adverse symptoms such as blood pressure can be provided.

Compositions and methods for preventing or reducing vasoconstriction in a mammal following administration of a vasoactive oxygen carrier (e.g., a heme-based oxygen carrier such as a hemoglobin-based oxygen carrier) are disclosed. The methods include administering to a mammal a composition containing a vasoactive oxygen carrier in combination with one or more of a nitric oxide-releasing compound, atherapeutic gas containing gaseous nitric oxide, a phosphodiesterase inhibitor, and/or a soluble guanylate cyclase sensitizer.